Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 8/20 | 0.32 |
| ▸ | DPP8 | Q6V1X1 | 7/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2394609 | 1.00 | DPP4 (0.32) | DPP4DPP8MEN1ALDH1A1MAPT | |
| SCHEMBL2378666 | 0.92 | CTSK (0.31) | — | |
| SCHEMBL2379450 | 0.92 | CTSK (0.31) | — | |
| SCHEMBL28043191 | 0.85 | MEN1 (0.36) | DPP4DPP8MEN1ALDH1A1MAPT | |
| SCHEMBL17500736 | 0.84 | — | — | |
| SCHEMBL334564 | 0.82 | F2R (0.31) | ALDH1A1 | |
| SCHEMBL28282832 | 0.76 | CTSK (0.36) | DPP4DPP8MEN1ALDH1A1MAPT | |
| SCHEMBL28259769 | 0.76 | CTSK (0.36) | DPP4DPP8MEN1ALDH1A1MAPT | |
| SCHEMBL28853721 | 0.76 | — | — | |
| SCHEMBL2571959 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116964046-B | PLK4 inhibitors and uses thereof | 上海齐鲁制药研究中心有限公司 | 2024-04-19 | — | — | CN | disclosed |
| CN-116964046-A | PLK4 inhibitors and uses thereof | 上海齐鲁制药研究中心有限公司 | 2023-10-27 | — | — | CN | disclosed |
| WO-2022184049-A1 | PLK4 INHIBITOR AND USE THEREOF | 上海齐鲁制药研究中心有限公司 | 2022-09-09 | — | — | WO | disclosed |
| US-8518945-B2 | Pyrrolopyrazine kinase inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2013-08-27 | — | — | US | disclosed |
| EP-2550273-A2 | PYRROLOPYRAZINE KINASE INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2013-01-30 | — | — | EP | disclosed |
| WO-2011117145-A2 | PYRROLOPYRAZINE KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-09-29 | — | — | WO | disclosed |
| US-20110230462-A1 | Pyrrolopyrazine Kinase Inhibitors | HENDRICKS ROBERT THAN | 2011-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230462-A1 | Pyrrolopyrazine Kinase Inhibitors | SYK, ZAP70, BTK | DPP4 2131/4885DPP8 3359/4885MEN1 4109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.